Last reviewed · How we verify
Metastasis from malignant tumor of prostate
Approved treatments
- Xtandi · Astellas Pharma
Xtandi works by blocking the androgen receptor, a protein that helps prostate cancer cells grow. - Erleada · Johnson & Johnson
Erleada blocks the androgen receptor, a protein that helps cancer cells grow. - MDV3100 · Pfizer Inc.
- Xtandi · Astellas Pharma
Enzalutamide competitively inhibits androgen binding to androgen receptors, blocking nuclear translocation and DNA interaction.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Metastasis from malignant tumor of prostate patent landscape — cliff calendar, originator estates, attackable patents
- Metastasis from malignant tumor of prostate treatment landscape brief
- Metastasis from malignant tumor of prostate treatment updates RSS
Frequently asked questions about Metastasis from malignant tumor of prostate
What drugs treat Metastasis from malignant tumor of prostate?
Tracked treatments include Xtandi, Erleada, MDV3100.
What is the treatment for Metastasis from malignant tumor of prostate?
Standard treatment for Metastasis from malignant tumor of prostate includes Xtandi, Erleada, MDV3100. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Metastasis from malignant tumor of prostate patent cliff · Metastasis from malignant tumor of prostate CI report
- Treatment: Xtandi · Astellas Pharma
- Treatment: Erleada · Johnson & Johnson
- Treatment: MDV3100 · Pfizer Inc.
- Treatment: Xtandi · Astellas Pharma
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing